Project Grant R21NS130095

Award Date 9/1/23
Completion Date 8/31/25
Dollars Obligated $475K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The federal Project Grant award of $173,140 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research to elucidate the role of neural activity in the degeneration of midbrain dopamine neurons in Parkinson's disease. The project aims to utilize novel mouse models to chronically manipulate the activity and dopamine metabolism within dopamine neurons,...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, provides $245,847.00 to Duke University to investigate the role of the Integrated Stress Response (ISR) pathway in dopamine neurons and its implications for Parkinson's disease. The project, titled "The ISR Pathway in Dopamine Neurons: Perpetrator or Protector in Parkinson's Disease," aims to examine ISR states in dopamine neuron subclasses in...
This $684,451 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports comprehensive research to advance understanding and treatment of Parkinson's disease (PD). The project aims to: Identify PD progression subtypes through integrative modeling of longitudinal clinical, transcriptomic, and neuroimaging data from the Parkinson's Progression...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $616,200.00 to support research into the influence of neuromelanin on single dopaminergic neurons in Parkinson's disease. The primary objective is to leverage expertise across three established labs to explore how progressive neuromelanin accumulation in dopamine...
This $163,750 federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify innovative drug candidates for treating Parkinson's disease (PD) and dementia with Lewy bodies (DLB) related to mutations in the GBA1 gene. The project aims to perform high-throughput screening of 11,280 small molecule compounds to boost...
The University of Pittsburgh received a $499,286.59 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The award supports research to elucidate the relationship between oxidative stress and LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Specifically, the project examines: (1) the oxidative activation of LRRK2, (2)...
This $406,260 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will support research to define the molecular mechanisms that contribute to neurodegeneration in Parkinson's disease (PD) and related dementias. The research aims to establish a role for alpha-synuclein-mediated membrane permeabilization in the spread of alpha-synuclein...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $646,104 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the San Diego Biomedical Research Institute, a non-profit research organization. The grant supports research to investigate how neuroinflammation mediated by the interleukin-13 receptor signaling pathway may contribute to the selective loss of dopaminergic neurons in Parkinson's disease. The...
This federal Project Grant award of $682,493 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program supports research to elucidate the role of aberrant histone acetylation in the pathogenesis of Parkinson's disease (PD) and related synucleinopathies. The primary goal is to leverage a human pluripotent stem cell-based discovery platform to investigate how disruption of...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), provides $858,471 to support research focused on understanding the role of N-terminal acetylation in alpha-synuclein stability, function, and therapeutic targeting for synucleinopathies like Parkinson's disease (PD) and Alzheimer's disease-related dementias (ADRD). The key objectives of this 5-year grant (award date: September 13, 2024) are...

This $475,475 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The goal of the award is to evaluate a small molecule inhibitor of the USP30 enzyme as a potential neuroprotective therapy for Parkinson's disease. The research will assess whether inhibiting USP30 can enhance mitophagy, the selective degradation of dysfunctional mitochondria, and thereby protect dopaminergic neurons from the toxicity of alpha-synuclein. The 2-year project will utilize a slowly progressive mouse model of Parkinson's disease to test the efficacy and mechanisms of this therapeutic strategy. If successful, these preclinical results could support the advancement of this USP30 inhibitor or related compounds towards clinical trials for neuroprotection in Parkinson's disease.

Generated 8/13/24, 9:34 AM